-
A.
Bois,
A.
Floquet,
Jae-Weon
Kim,
J.
Rau,
J.
Campo,
M.
Friedlander,
S.
Pignata,
K.
Fujiwara,
I.
Vergote,
N.
Colombo,
M.
Mirza,
B.
Monk,
R.
Kimmig,
I.
Ray-Coquard,
R.
Zang,
I.
Díaz-Padilla,
K.
Baumann,
M.
Mouret-Reynier,
Jae-Hoon
Kim,
C.
Kurzeder,
A.
Lesoin,
P.
Vasey,
C.
Marth,
U.
Canzler,
G.
Scambia,
M.
Shimada,
P.
Calvert,
E.
Pujade-Lauraine,
Byoung-Gie
Kim,
T.
Herzog,
I.
Mitrica,
C.
Schade-Brittinger,
Qiong
Wang,
R.
Crescenzo,
P.
Harter
(2014)
Incorporation of pazopanib in maintenance therapy of ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32 30
-
A.
Bois,
G.
Kristensen,
I.
Ray-Coquard,
A.
Reuss,
S.
Pignata,
N.
Colombo,
U.
Denison,
I.
Vergote,
J.
Campo,
P.
Ottevanger,
M.
Heubner,
T.
Minarik,
E.
Sevin,
N.
Gregorio,
M.
Bidziński,
J.
Pfisterer,
S.
Malander,
F.
Hilpert,
M.
Mirza,
G.
Scambia,
W.
Meier,
M.
Nicoletto,
L.
Bjørge,
A.
Lortholary,
M.
Sailer,
M.
Merger,
P.
Harter
(2016)
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
The Lancet. Oncology, 17 1
-
Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens
-
(2016)
A phase III trial of bevacizumab with IV versus IP chemotherapy in ovarian, fallopian tube, and peritoneal carcinoma NCI-supplied agent(s): a GOG/NRG trial (GOG 252)
-
R.
Burger,
M.
Brady,
M.
Bookman,
G.
Fleming,
B.
Monk,
Helen
Huang,
R.
Mannel,
H.
Homesley,
J.
Fowler,
B.
Greer,
M.
Boente,
M.
Birrer,
S.
Liang
(2011)
Incorporation of bevacizumab in the primary treatment of ovarian cancer.
The New England journal of medicine, 365 26
-
J.
Chan,
M.
Brady,
R.
Penson,
Helen
Huang,
M.
Birrer,
J.L.
Walker,
P.
DiSilvestro,
S.
Rubin,
Lainie
Martin,
S.
Davidson,
W.
Huh,
D.
O’Malley,
M.
Boente,
Helen
Michael,
B.
Monk
(2016)
Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer.
The New England journal of medicine, 374 8
-
A.
Bois,
A.
Reuss,
E.
Pujade-Lauraine,
P.
Harter,
I.
Ray-Coquard,
J.
Pfisterer
(2009)
Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials
Cancer, 115
-
Neil
Horowitz,
Austin
Miller,
B.
Rungruang,
Scott
Richard,
N.
Rodriguez,
M.
Bookman,
Chad
Hamilton,
T.
Krivak,
G.
Maxwell
(2015)
Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182.
Obstetrical & Gynecological Survey
-
S.
Pignata,
G.
Scambia,
D.
Katsaros,
C.
Gallo,
E.
Pujade-Lauraine,
S.
Placido,
A.
Bologna,
B.
Weber,
F.
Raspagliesi,
P.
Panici,
G.
Cormio,
R.
Sorio,
M.
Cavazzini,
G.
Ferrandina,
E.
Breda,
V.
Murgia,
C.
Sacco,
S.
Cinieri,
V.
Salutari,
C.
Ricci,
C.
Pisano,
S.
Greggi,
R.
Lauria,
D.
Lorusso,
C.
Marchetti,
L.
Selvaggi,
S.
Signoriello,
M.
Piccirillo,
M.
Maio,
F.
Perrone
(2014)
Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.
The Lancet. Oncology, 15 4
-
A.
Karam,
J.
Ledermann,
Jae
Kim,
J.
Sehouli,
K.
Lu,
C.
Gourley,
N.
Katsumata,
R.
Burger,
B.
Nam,
M.
Bacon,
C.
Ng,
J.
Pfisterer,
R.
Bekkers,
A.
Herráez,
A.
Redondo,
H.
Fujiwara,
N.
Gleeson,
O.
Rosengarten,
G.
Scambia,
Jianqing
Zhu,
A.
Okamoto,
G.
Stuart,
K.
Ochiai
(2017)
Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions.
Annals of oncology : official journal of the European Society for Medical Oncology, 28 4
-
N.
Katsumata,
M.
Yasuda,
F.
Takahashi,
S.
Isonishi,
T.
Jobo,
D.
Aoki,
H.
Tsuda,
T.
Sugiyama,
S.
Kodama,
E.
Kimura,
K.
Ochiai,
K.
Noda
(2009)
Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial
The Lancet, 374
-
E.
Dean,
Mark
Middleton,
T.
Pwint,
H.
Swaisland,
Joseph
Carmichael,
P.
Goodege-Kunwar,
Malcolm
Ranson
(2012)
Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours
British Journal of Cancer, 106
-
T.
Perren,
A.
Swart,
J.
Pfisterer,
J.
Ledermann,
E.
Pujade-Lauraine,
G.
Kristensen,
M.
Carey,
P.
Beale,
A.
Cervantes,
C.
Kurzeder,
A.
Bois,
J.
Sehouli,
R.
Kimmig,
A.
Stähle,
F.
Collinson,
S.
Essapen,
C.
Gourley,
A.
Lortholary,
F.
Selle,
M.
Mirza,
A.
Leminen,
M.
Plante,
D.
Stark,
W.
Qian,
M.
Parmar,
A.
Oza
(2011)
A phase 3 trial of bevacizumab in ovarian cancer.
The New England journal of medicine, 365 26
-
J.
Hamanishi,
M.
Mandai,
T.
Ikeda,
M.
Minami,
A.
Kawaguchi,
T.
Murayama,
M.
Kanai,
Y.
Mori,
S.
Matsumoto,
S.
Chikuma,
N.
Matsumura,
K.
Abiko,
T.
Baba,
K.
Yamaguchi,
Akihiko
Ueda,
Y.
Hosoe,
S.
Morita,
M.
Yokode,
Akira
Shimizu,
T.
Honjo,
I.
Konishi
(2015)
Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 34
-
J.
Neijt,
S.
Engelholm,
M.
Tuxen,
P.
Sørensen,
M.
Hansen,
C.
Sessa,
C.
Swart,
F.
Hirsch,
B.
Lund,
H.
Houwelingen
(2000)
Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 18 17
-
(2013)
Appendix 1 to the guideline on the evaluation of anticancer medicinal products in man
-
M.
Bookman,
M.
Brady,
W.
Mcguire,
P.
Harper,
D.
Alberts,
M.
Friedlander,
N.
Colombo,
J.
Fowler,
P.
Argenta,
K.
Geest,
D.
Mutch,
R.
Burger,
A.
Swart,
E.
Trimble,
Chrisann
Accario-Winslow,
L.
Roth
(2009)
Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 9
-
A.
Bois,
H.
Lück,
W.
Meier,
H.
Adams,
V.
Möbus,
S.
Costa,
T.
Bauknecht,
B.
Richter,
M.
Warm,
W.
Schröder,
S.
Olbricht,
U.
Nitz,
C.
Jackisch,
G.
Emons,
U.
Wagner,
W.
Kuhn,
J.
Pfisterer
(2003)
A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.
Journal of the National Cancer Institute, 95 17
-
R.
Ozols,
B.
Bundy,
B.
Greer,
J.
Fowler,
D.
Clarke‐Pearson,
R.
Burger,
R.
Mannel,
K.
Degeest,
E.
Hartenbach,
R.
Baergen
(2003)
Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 21 17
-
J.
Radford
(2016)
Nivolumab for recurrent squamous-cell carcinoma of the head and neck
BDJ, 221
-
J.
Wright,
Ling
Chen,
A.
Tergas,
S.
Patankar,
W.
Burke,
J.
Hou,
A.
Neugut,
C.
Ananth,
D.
Hershman
(2015)
Trends in Relative Survival for Ovarian Cancer From 1975 to 2011
Obstetrics & Gynecology, 125
-
A.
Bois,
B.
Weber,
J.
Rochon,
W.
Meier,
A.
Goupil,
S.
Olbricht,
J.
Barats,
W.
Kuhn,
H.
Orfeuvre,
U.
Wagner,
B.
Richter,
H.
Lueck,
J.
Pfisterer,
S.
Costa,
W.
Schroeder,
R.
Kimmig,
E.
Pujade-Lauraine
(2006)
Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationau
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 7
-
L.
Randall,
R.
Burger,
H.
Nguyen,
G.
Kong,
M.
Bookman,
G.
Fleming,
B.
Monk,
R.
Mannel,
M.
Birrer
(2013)
Outcome differences in patients with advanced epithelial ovarian, primary peritoneal and fallopian tube cancers treated with and without bevacizumab
Gynecologic Oncology, 130
-
Joyce
Liu,
William
Barry,
M.
Birrer,
Jung-Min
Lee,
R.
Buckanovich,
G.
Fleming,
Bj
Rimel,
M.
Buss,
S.
Nattam,
J.
Hurteau,
W.
Luo,
P.
Quy,
C.
Whalen,
Lisa
Obermayer,
Hang
Lee,
Eric
Winer,
E.
Kohn,
S.
Ivy,
U.
Matulonis
(2014)
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.
The Lancet. Oncology, 15 11
-
J.
Ledermann,
P.
Harter,
C.
Gourley,
M.
Friedlander,
I.
Vergote,
G.
Rustin,
Clare
Scott,
W.
Meier,
R.
Shapira-Frommer,
T.
Safra,
D.
Matei,
A.
Fielding,
S.
Spencer,
B.
Dougherty,
M.
Orr,
D.
Hodgson,
J.
Barrett,
U.
Matulonis
(2014)
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.
The Lancet. Oncology, 15 8
-
A.
Clamp,
I.
McNeish,
A.
Dean,
D.
Gallardo,
J.
Weon-Kim,
D.
O'Donnell,
J.
Hook,
C.
Coyle,
S.
Blagden,
J.
Brenton,
R.
Naik,
T.
Perren,
S.
Sundar,
A.
Cook,
E.
James,
A.
Swart,
S.
Stenning,
R.
Kaplan,
J.
Ledermann
(2017)
ICON8: A GCIG phase III randomised trial evaluating weekly dosedense chemotherapy integration in first- line epithelial ovarian/fallopian tube/primary peritoneal carcinoma (EOC) treatment: Results of primary progression- free survival (PFS) analysis
Annals of Oncology, 28
-
M.
Piccart,
K.
Bertelsen,
Gavin
Stuart,
Jim
Cassidy,
C.
Mangioni,
E.
Simonsen,
Keith
James,
S.
Kaye,
I.
Vergote,
R.
Blom,
R.
Grimshaw,
R.
Atkinson,
Ken
Swenerton,
C.
Tropé,
M.
Nardi,
J.
Kaern,
Salvatore
Tumolo,
P.
Timmers,
Josee
Roy,
F.
Lhoas,
B.
Lidvall,
Monica
Bacon,
A.
Birt,
J.
Andersen,
B.
Zee,
James
Paul,
S.
Pecorelli,
Benoit
Baron,
W.
Mcguire
(2003)
Long‐term follow‐up confirms a survival advantage of the paclitaxel–cisplatin regimen over the cyclophosphamide–cisplatin combination in advanced ovarian cancer
International Journal of Gynecological Cancer, 13
-
D.
Tewari,
J.
Java,
R.
Salani,
D.
Armstrong,
M.
Markman,
T.
Herzog,
B.
Monk,
J.
Chan
(2015)
Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study.
Obstetrical & Gynecological Survey
-
A.
Oza,
A.
Cook,
J.
Pfisterer,
A.
Embleton,
J.
Ledermann,
E.
Pujade-Lauraine,
G.
Kristensen,
M.
Carey,
P.
Beale,
A.
Cervantes,
T.
Park-Simon,
G.
Rustin,
F.
Joly,
M.
Mirza,
M.
Plante,
M.
Quinn,
A.
Poveda,
G.
Jayson,
D.
Stark,
A.
Swart,
L.
Farrelly,
R.
Kaplan,
M.
Parmar,
T.
Perren
(2015)
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial
The Lancet. Oncology, 16
-
V.
Möbus,
H.
Wandt,
N.
Frickhofen,
C.
Bengala,
K.
Champion,
R.
Kimmig,
H.
Ostermann,
A.
Hinke,
J.
Ledermann
(2007)
Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 27
-
Noriyuki
Katsumata,
M.
Yasuda,
S.
Isonishi,
H.
Michimae,
E.
Kimura,
D.
Aoki,
T.
Jobo,
S.
Kodama,
F.
Terauchi,
H.
Tsuda,
T.
Sugiyama,
K.
Ochiai
(2012)
Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trial.
Journal of Clinical Oncology, 30
-
A.
Oza,
D.
Cibula,
A.
Benzaquén,
C.
Poole,
R.
Mathijssen,
G.
Sonke,
N.
Colombo,
J.
Špaček,
P.
Vuylsteke,
H.
Hirte,
S.
Mahner,
M.
Plante,
B.
Schmalfeldt,
H.
Mackay,
J.
Rowbottom,
E.
Lowe,
B.
Dougherty,
J.
Barrett,
M.
Friedlander
(2015)
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
The Lancet. Oncology, 16 1
-
U.
Matulonis,
P.
Harter,
C.
Gourley,
M.
Friedlander,
I.
Vergote,
G.
Rustin,
C.
Scott,
W.
Meier,
R.
Shapira-Frommer,
T.
Safra,
D.
Matei,
A.
Fielding,
S.
Spencer,
D.
Parry,
L.
Grinsted,
J.
Ledermann
(2016)
Olaparib maintenance therapy in patients with platinum‐sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy
Cancer, 122
-
Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO)
-
S.
Temkin,
M.
Terplan
(2015)
Trends in Relative Survival for Ovarian Cancer From 1975-2011.
Obstetrics & Gynecology
-
R.
Bristow,
Rafael
Tomacruz,
D.
Armstrong,
E.
Trimble,
F.
Montz
(2002)
Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 5
-
W.
Driel,
S.
Koole,
K.
Sikorska,
J.
Leeuwen,
H.
Schreuder,
R.
Hermans,
I.
Hingh,
J.
Velden,
H.
Arts,
L.
Massuger,
A.
Aalbers,
V.
Verwaal,
J.
Kieffer,
K.
Vijver,
H.
Tinteren,
N.
Aaronson,
G.
Sonke
(2018)
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
The New England Journal of Medicine, 378